Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × bicalutamide × 90 days × Clear all

Phase

Phase 2 6 Phase 3 4 Phase 4 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostate Adenocarcinoma 1

Interventions

Specimen Handling 115 pembrolizumab 110 Cyclophosphamide 95 Magnetic Resonance Spectroscopy 89 Biopsy 87 fludarabine 72 Nivolumab 51 venetoclax 48 Radiotherapy 33 Cetuximab 32 Carboplatin 31 fludarabine phosphate 30 Paclitaxel 30 Gemcitabine 30 Bevacizumab 30 Cisplatin 28 atezolizumab 26 Fluorouracil 26 Azacitidine 26 Ipilimumab 24 Cytarabine 24 durvalumab 23 Injections 23 Dexamethasone 23 Temozolomide 22 Radiosurgery 22 Lenalidomide 22 Oxaliplatin 21 Irinotecan 21 olaparib 19

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04943536 2026-02-27

BiolenRT

Alessa Therapeutics Inc.

Phase 1 Active not recruiting

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡